Striving for Consensus on Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids: Discussions from the First Category 1 Focus Group Meeting.
PinneyAssociates, Bethesda, Maryland, U.S.A.
Edward J
EJ
Cone
Grünenthal USA Inc., Morristown, New Jersey, U.S.A.
Marta
M
Sokolowska
Egalet Corporation, Wayne, Pennsylvania, U.S.A. KLindhardt@egalet.com.
Karsten
K
Lindhardt